Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, November 26, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
New Test Developed at Dana-Farber/Brigham and Women's Cancer Center
Rapid Heme Panel - A high-tech genetic test that speeds treatment decisions for blood cancer patients.
Researchers Silence Leading Cancer-Causing Gene
A novel siRNA-based molecule successfully targets KRAS, a well-studied but hard to halt protein important for cancer development and metastasis.
Tumor Suppressor Also Inhibits Key Property Of Stem Cells
The retinoblastoma protein inhibits cancer by controlling cell division. Now, researchers have shown that it also binds to and inhibits genes necessary for pluripotency.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Next-Gen Melanoma Drug Excels in Lab Tests
Anti-cancer activity was reported in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733.
Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors
Lays groundwork for development of new therapies.
Light Shed On Genetic Architecture Of Kidney Cancer
Research reveals link between renal cell carcinoma and exposure to aristolochic acid.
Salk Scientists Discover a Key to Mending Broken Hearts
Researchers regenerate and heal mouse hearts by using the molecular machinery the animals had all along.
Scroll Up
Scroll Down
Return
Efficient and Specific Quantification of Mammalian microRNAs by a Novel Real-Time PCR Approach
Eric Lader, Director, QIAGEN, speaking at the RNAi World Congress 2007
Date Posted: Wednesday, December 19, 2007
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN to Acquire SABiosciences
Transaction adds to QIAGEN’s content engine for development of future diagnostics and boosts the Company’s presence in pharma discovery and validation.
Tuesday, November 10, 2009
Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention
The Nobel Prize-winning discovery of the causal link between human papillomavirus (HPV) and cervical cancer has spurred lifesaving prevention technologies – such as HPV testing and HPV vaccines - that are helping to eradicate cervical cancer globally.
Tuesday, October 07, 2008
Qiagen Forms a User Forum for High-Throughput RNAi Screening
The user forum aims to facilitate advances in RNAi screening in drug target identification and systems biology.
Tuesday, March 28, 2006
Qiagen Develops Leading Solutions for RNA Interference
Qiagen will develop world’s largest collection of validated siRNAs through an extensive validation project.
Tuesday, December 13, 2005
Qiagen Delivers the Human Druggable Genome siRNA Set
This second generation siRNA set enables gene silencing studies of 6992 potential human druggable targets.
Friday, September 30, 2005
 
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv